SEATTLE, May 2, 2023 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new…Read More
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635c4
